Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $28.02 --0%
Revenue Growth %: +19.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +19.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Guggenheim Reiterates Buy Rating on Oracle (ORCL)
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
